Company Overview
About DNA Script
DNA Script is a biotechnology company founded in 2014 and headquartered in Paris, France (with US operations in South San Francisco), that has developed a breakthrough enzymatic DNA synthesis (EDS) platform. Traditional chemical-based DNA synthesis — the process of producing custom DNA sequences used in genomics, synthetic biology, diagnostics, and therapeutic development — relies on hazardous chemicals and generates significant toxic waste. DNA Script's approach replaces these chemicals with enzymes (specifically terminal deoxynucleotidyl transferase, or TdT), enabling faster, greener, and more scalable DNA production at the benchtop.
Business Model & Competitive Advantage
The company has raised $335M in total funding, including a $165M oversubscribed Series C and a $50M Series C extension in Q3 2024. Its flagship product, the SYNTAX System, is a benchtop enzymatic DNA synthesis printer that lets researchers produce custom oligonucleotides on demand within hours — compared to the days or weeks required to order from external synthesis providers. In 2025, DNA Script received CE Mark approval for the SYNTAX System, enabling it to be used in clinical laboratories across Europe — a significant regulatory milestone that expands the platform's addressable market into diagnostics and clinical research. The company also received a $2.2M NIH grant from the National Human Genome Research Institute to develop next-generation enzymatic DNA synthesis printers.
Competitive Landscape 2025–2026
DNA Script serves pharmaceutical, biotech, and academic research customers that require rapid, flexible access to custom DNA sequences. The on-demand benchtop model eliminates lead times and reduces costs associated with outsourcing synthesis — particularly valuable for iterative drug discovery workflows, CRISPR guide RNA development, and synthetic biology research where rapid design-test cycles are essential.
Key Differentiators
Strong Challenger
DNA Script is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare DNA Script with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from DNA Script? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim DNA Script Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention DNA Script vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →